FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Jun Yan(Capital Medical University), Shulin Li(The University of Texas MD Anderson Cancer Center)

Nature Communications

January 25, 2019

10.1038/s41467-018-08271-x

Cited by 119

Related Papers

EMT, CTCs and CSCs in tumor relapse and drug-resistance

|Oncotarget|2015|464

Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

|Scientific Reports|2016|195

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement

|The Lancet Haematology|2019|82

IL6‐mediated inflammatory loop reprograms normal to epithelial‐mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta–deficient β2‐spectrin+/− mice

|Hepatology|2016|66

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

|Nature Reviews Clinical Oncology|2021|58